Buy Cilostazol

Cilostazol

Cilostazol: Generic Medication Overview

Cilostazol is a prescription-only pill used to improve walking distance in people with peripheral arterial disease (PAD)-related intermittent claudication. It belongs to the cardiovascular therapeutic class and works by inhibiting an enzyme called phosphodiesterase-3 (PDE3). In the UK, cilostazol is authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) and is available in 50 mg and 100 mg tablet strengths.

How Cilostazol Works in the Body

Cilostazol is a selective phosphodiesterase-3 inhibitor. By blocking PDE3, it raises intracellular cyclic adenosine monophosphate (cAMP) levels in platelets and vascular smooth-muscle cells. The increased cAMP produces two clinically relevant effects:

• Platelet inhibition: Higher cAMP reduces platelet aggregation, decreasing the tendency for small clots to form in the arteries of the legs.
• Vasodilation: Elevated cAMP relaxes smooth-muscle cells, widening peripheral blood vessels and improving blood flow to the leg muscles during exercise.

These actions combine to lessen the pain and fatigue that occur when walking with PAD, allowing patients to cover longer distances before symptoms return. The onset of benefit typically appears after several weeks of consistent therapy, as the vascular adaptations develop gradually.

Conditions Treated by Cilostazol

Cilostazol is approved in the United Kingdom for the symptomatic treatment of intermittent claudication caused by peripheral arterial disease. It is not indicated for other cardiovascular conditions such as angina, hypertension, or heart failure. The medication is prescribed for adult patients who experience leg pain on exertion that improves with rest, and whose disease severity is classified as Fontaine stage II or Rutherford category 1-3.

Off-Label Uses

Current peer-reviewed evidence does not support any off-label applications of cilostazol that meet the criteria for inclusion. Clinicians may encounter isolated case reports exploring its use in other vascular disorders, but these are not backed by robust clinical trials and are therefore omitted from this overview.

Who Should (Not) Use Cilostazol?

Ideal patient profile

• Adults with confirmed peripheral arterial disease presenting intermittent claudication.
• Patients who have not achieved satisfactory improvement with supervised exercise programmes or lifestyle modification alone.

Absolute contraindications

• Known hypersensitivity to cilostazol or any of its excipients.
• Congestive heart failure (NYHA class III or IV).
• Active or recent (within 3 months) bleeding disorders, including gastrointestinal ulcers.
• Severe hepatic impairment (Child-Pugh C).
• Pregnancy (category X) or lactation - cilostazol is contraindicated because of potential fetal toxicity.

Relative contraindications / cautions

• Moderate hepatic impairment (Child-Pugh A or B). Dose adjustment or close monitoring may be needed.
• Chronic kidney disease with estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m² - limited data, use only if benefits outweigh risks.
• Elderly patients (≥ 75 years) - increased susceptibility to hypotension and dizziness; start at the lower dose.
• Concomitant use of other antiplatelet agents (e.g., clopidogrel, aspirin) - may heighten bleeding risk.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Headache (often transient).
• Palpitations or tachycardia.
• Diarrhoea or abdominal discomfort.
• Dizziness, especially when standing quickly.

These reactions are usually mild and tend to improve with continued therapy or dose adjustment.

Serious Adverse Events

• Severe bleeding (e.g., gastrointestinal, intracranial).
• Worsening of heart failure symptoms (dyspnoea, peripheral oedema).
• Very rare cases of hepatotoxicity presenting with jaundice or elevated liver enzymes.

Any of these signs require immediate medical attention.

Drug Interactions

• Major: Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can raise cilostazol plasma concentrations, increasing the risk of adverse effects.
• Moderate: Dual antiplatelet therapy (aspirin + clopidogrel) or anticoagulants (warfarin, DOACs) may compound bleeding risk; clinicians should monitor coagulation parameters.
• CYP3A4 inducers such as rifampicin, carbamazepine, or St. John’s wort may reduce cilostazol efficacy.

Food and Lifestyle Interactions

• Alcohol: Excessive intake can potentiate dizziness and hypotension. Moderate consumption is generally acceptable but should be discussed with a prescriber.
• Driving: Patients experiencing dizziness or palpitations should avoid operating heavy machinery until they know how cilostazol affects them.
• Dietary restrictions: No specific food interactions are documented, but a balanced diet supporting vascular health is advisable.

How to Take Cilostazol

• Standard dosing: The usual adult regimen starts with a 50 mg tablet taken twice daily (morning and evening) taken with food to reduce gastrointestinal upset. After two weeks, the dose may be increased to 100 mg twice daily if tolerability allows and clinical benefit is insufficient.
• Administration: Swallow tablets whole with a glass of water. Do not crush or chew.
• Missed dose: If a dose is forgotten and it is less than 6 hours until the next scheduled dose, take it as soon as remembered. Skip the missed dose if it is close to the next dose; do not double-dose.
• Overdose: Symptoms may include severe nausea, vomiting, dizziness, or rapid heart rate. Seek emergency medical care; supportive care is the mainstay of treatment. There is no specific antidote.
• Discontinuation: Cilostazol can be stopped abruptly, but clinicians often taper the dose over a week to monitor for rebound claudication symptoms.

Monitoring and Follow-Up

• Baseline assessments: Liver function tests (ALT, AST, bilirubin) and renal function (serum creatinine, eGFR) before initiating therapy.
• Periodic checks: Repeat liver enzymes after 4-6 weeks, then every 3-6 months as clinically indicated. Monitor for signs of bleeding or worsening heart failure.
• Efficacy: Walking distance (e.g., 6-minute walk test) should be measured after 3 months of therapy to gauge improvement.
• When to contact a healthcare professional: New or worsening chest pain, sudden shortness of breath, severe abdominal pain, or signs of bleeding.

Storage and Handling

• Store cilostazol tablets at room temperature (15-25 °C), protected from moisture and direct sunlight.
• Keep the medication out of reach of children and pets.
• Do not use tablets beyond the expiry date printed on the packaging.
• Unused tablets should be disposed of via a pharmacy take-back program or according to local waste-disposal guidelines.

Medication-Specific Glossary

Phosphodiesterase-3 (PDE3) inhibition

The process by which cilostazol blocks the enzyme PDE3, leading to increased cAMP levels in platelets and vascular smooth-muscle cells.

cAMP (cyclic adenosine monophosphate)

A secondary messenger molecule that promotes vasodilation and reduces platelet aggregation when its intracellular concentration rises.

Intermittent claudication

Leg pain or cramping caused by insufficient blood flow during exercise, characteristic of peripheral arterial disease.

Peripheral arterial disease (PAD)

Atherosclerotic narrowing of arteries in the limbs, most commonly affecting the legs and leading to reduced perfusion.

Medical Disclaimer

This article provides educational information about cilostazol and is not a substitute for professional medical advice. Treatment decisions, including the use of cilostazol for any indication, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes only and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.